Study of LXE408 for people with chronic Chagas disease
Part of Infections clinical trials.
This trial tests a new drug called LXE408 for people with chronic Chagas disease. It aims to see if the drug is safe and effective, and participants will also receive standard treatment with benznidazole.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You have a confirmed diagnosis of Chagas disease and are in the chronic (long-term) phase
- You have not been treated for Chagas disease with benznidazole or nifurtimox before
- You weigh between 50 and 90 kg (about 110 to 198 pounds)
- You do not have serious heart or digestive problems from Chagas disease
- You are willing to use effective birth control if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a shorter course of benznidazole (a medicine for Chagas disease) to the standard longer treatment. It aims to see if the shorter regimen works as well and is safe for people with confirmed Chagas infection.
This is an observational study that follows pregnant people who took nifurtimox during pregnancy. Researchers want to better understand the risk of pregnancy complications and check both mother’s and baby’s health over time.
This trial tests a new medicine called LY4088044 in healthy people to see how it affects the body. It helps doctors learn about the drug's safety before testing it in patients with a disease.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This trial is testing new rapid diagnostic tests to detect infection with Trypanosoma cruzi, which causes Chagas disease. It aims to find faster ways to diagnose people who may be at risk, such as pregnant women, blood donors, or those with possible chronic infection.
This study tests two new oral medicines compared to an existing oral medicine for people with a first episode of cutaneous leishmaniasis (skin sores caused by a parasite). It aims to find a more effective and convenient treatment.
Hear when a new Chagas Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.